LUCD · XBRL financial data

Lucid Diagnostics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (LUCD's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	783	1,040*	1,001	976	1,172	1,197*	828	1,163	1,211	—	—	—
Revenue from contracts with customers	783	1,040*	1,001	976	1,172	1,197*	828	1,163	1,211	—	—	—
Cost of revenue	—	—	—	—	—	year only	1,551	1,563	—	year only	1,625	1,445
Research and development	1,615	1,918*	1,501	1,372	1,666	1,453*	1,428	1,255	1,272	1,723*	1,206	1,192
General and administrative	4,320	4,205*	4,070	4,867	5,355	5,864*	6,162	5,617	5,605	6,484*	5,432	5,757
Total operating expenses	11,911	12,493*	11,793	12,168	12,866	13,572*	13,315	12,547	12,970	—	—	—
Operating income (loss)	(11,128)	(11,453)*	(10,792)	(11,192)	(11,694)	(12,375)*	(12,487)	(11,384)	(11,759)	(14,011)*	(12,114)	(12,801)
Interest income	—	—	—	—	—	year only	66	110	—	year only	70	77
Interest expense	149	11*	12	6	1	7*	9	6	2	6*	6	4
Other income (expense)	(3,080)	623*	180	187	(677)	834*	(14,421)	6,945	1,362	—	—	—
Income tax expense (benefit)	—	—	—	—	—	year only	0	0	—	year only	0	0
Net income (loss)	(14,208)	(10,830)*	(10,612)	(11,005)	(12,371)	(11,541)*	(26,908)	(4,439)	(10,397)	(16,266)*	(13,909)	(11,687)
Earnings per share, basic USD per share	(0.34)	(0.26)*	(0.40)	(0.23)	(0.25)	(0.20)*	(0.52)	(0.08)	(0.10)	—	(0.17)	(0.08)
Earnings per share, diluted USD per share	(0.34)	(0.26)*	(0.40)	(0.23)	(0.25)	(0.20)*	(0.52)	(0.08)	(0.10)	—	—	—
Weighted average shares, basic thousands of shares	41,863	42,341*	45,014	48,212	50,374	58,378*	68,796	98,989	108,176	—	140,097	183,124
Weighted average shares, diluted thousands of shares	41,863	42,341*	45,014	48,212	50,374	58,378*	68,796	98,989	108,176	—	—	—

Balance sheet

CSV

Fiscal quarters (LUCD's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	24,050	18,896	24,769	24,920	14,489	22,358	25,238	31,123	47,332	34,705	27,876	33,404
Accounts receivable	21	45	49	160	39	45	61	373	550	643	689	1,088
Inventory	—	278	410	683	651	341	484	505	486	353	469	484
Prepaid and other current assets	3,232	2,854	2,355	2,184	1,645	2,404	1,754	1,832	1,474	1,767	2,328	1,647
Total current assets	27,303	22,073	27,583	27,947	16,824	25,148	27,537	33,833	49,842	37,468	31,362	36,623
Property and equipment, net	1,284	1,334	1,242	1,050	940	1,062	1,040	948	862	809	907	810
Right-of-use asset	1,594	1,307	1,039	3,037	2,860	2,637	2,454	2,238	2,021	1,806	1,591	1,398
Total assets	33,244	27,270	32,048	34,113	22,598	30,715	32,795	38,670	53,198	40,445	34,080	38,946
Accounts payable	994	1,146	969	903	1,135	1,241	829	833	751	970	1,077	667
Accrued liabilities	—	—	—	—	—	2,829	—	—	—	2,719	2,200	2,443
Total current liabilities	30,224	29,382	19,977	15,980	14,249	23,524	36,569	29,426	26,206	28,582	29,385	27,516
Lease liability, non-current	464	199	177	2,154	2,011	1,800	1,603	1,382	1,157	927	695	503
Total liabilities	30,688	29,581	20,154	18,134	16,260	25,324	38,172	30,808	27,363	29,509	30,080	28,019
Accumulated deficit	(139,911)	(150,741)	(168,849)	(179,854)	(192,225)	(203,766)	(239,784)	(247,672)	(258,069)	(274,335)	(297,963)	(312,678)
Total stockholders' equity	2,556	(2,311)	11,894	15,979	6,338	5,391	(5,377)	7,862	25,835	10,936	4,000	10,927
Total liabilities and equity	33,244	27,270	32,048	34,113	22,598	30,715	32,795	38,670	53,198	40,445	34,080	38,946
Common shares outstanding (cover page) thousands of shares	44,667	48,245	49,045	53,242	55,495	66,969	90,959	108,411	137,509	176,946	203,067	203,244

Cash flows

CSV

Fiscal quarters (LUCD's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(14,208)	(10,830)*	(10,612)	(11,005)	(12,371)	(11,541)*	(26,908)	(4,439)	(10,397)	(16,266)*	(13,909)	(11,687)
Stock-based compensation	1,032*	748*	743	1,107*	1,184*	1,149*	949	1,143*	1,135*	—	—	—
Depreciation and amortization	625*	629*	501	229*	215*	222*	221	222*	220*	209*	222	224*
Net cash from operating activities	(8,781)*	(9,979)*	(12,612)	(11,482)*	(10,175)*	(9,871)*	(12,465)	(10,549)*	(10,893)*	(12,578)*	(12,101)	(11,297)*
Purchases of property and equipment	—	—	—	—	—	year only	93	25*	—	year only	215	21*
Net cash from investing activities	(14)*	(175)*	(37)	0*	(350)*	(259)*	(93)	(25)*	(28)*	(51)*	(215)	(21)*
Net cash from financing activities	275*	5,000*	18,522	11,633*	94*	17,999*	15,438	16,459*	27,130*	2*	5,487	16,846*
Net change in cash	(8,520)*	(5,154)*	5,873	151*	(10,431)*	7,869*	2,880	5,885*	16,209*	(12,627)*	(6,829)	5,528*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Lucid Diagnostics	33,404	not reported	(11,297)*	203.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Apyx Medical	27,617	13,884	(3,490)*	42.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Encision	72	1,528	(127)*	16.9M	0.6 quarters	Q2 FY26 10-QSep 30, 2025
Accuray	40,623	100,919*	2,427*	119.4M	—	Q4 FY26 10-KJun 30, 2026
TELA Bio	30,424	19,291	(9,381)*	44.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
enVVeno Medical	2,585	not reported	(3,178)*	694,826	5.6 quarters	Q3 FY26 10-QSep 30, 2026
Fonar	53,650	26,472	1,580*	not reported	—	Q3 FY26 10-QMar 31, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Microbot Medical	3,152	241	(4,989)*	67.2M	13.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.